Mab labelled liposomes as selective vehicles for drugs in H.I.V. infected cells.
Being able to carry zidovudine (AZT) at known concentrations into CD4+/CD38+ and CD14+ cells permits: - to reduce the drug dosage and to increase the interval for administration (until 1 dose I.V. every week); - to modulate the drug concentration into the CD4+/CD38 an CD14+ cells in relation to the "in vitro" determined HIV sensitiveness; - to eliminate haematological, medullary and general toxicity; - to be able to treat severely hill patients. Further studies are necessary in order to: - To find out the better phase to start the therapy; - To use several drugs with different mechanisms of action in order to slow down as much as possible the presence of resistant viral strains. - As for other drugs which are beginning to be used with artificial vehicles, futher studies are required to improve the selectivity and safety of LIPOAZT for the target cells including macrophages.